Research Article

Long Noncoding RNA MIR100HG Knockdown Attenuates Hepatocellular Carcinoma Progression by Regulating MicroRNA-146b-5p/Chromobox 6

Fushun Li,1 Xianghua Sun,1 Qing Liu,1 Xilu Liu,1 and Jia Zhang2

1Department of Hepatobiliary Surgery, Wei Fang Yi Du Central Hospital, No. 4318, South Linglong Mountain Road, Qingzhou County, Weifang City, Shandong Province 262500, China
2Health Care Department I, Weifang People’s Hospital, No. 151, Guangwen Street, Kuiwen District, Weifang City, Shandong Province 261041, China

Correspondence should be addressed to Jia Zhang; zhangjia3322020@163.com

Received 24 May 2021; Revised 8 July 2021; Accepted 14 July 2021; Published 2 August 2021

Academic Editor: Nicola Silvestris

Copyright © 2021 Fushun Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. Hepatocellular carcinoma (HCC) accounts for approximately ninety percent of primary liver cancer. This study attempted to investigate the effects of the long noncoding RNA MIR100HG (MIR100HG) in HCC and the underlying molecular mechanism.

Materials and Methods. qRT-PCR was implemented to analyze the expression of MIR100HG, microRNA-146b-5p (miR-146b-5p), and Chromobox 6 (CBX6). The correlation between MIR100HG and clinicopathological features of HCC patients was assessed. Additionally, the effects of MIR100HG knockdown on HCC cell viability, migration, and invasion were explored. The interactions among MIR100HG, miR-146b-5p, and CBX6 were confirmed. Furthermore, rescue experiments were conducted to investigate whether MIR100HG knockdown modulates HCC cell behaviors through modulating the miR-146b-5p/CBX6 axis.

Results. The expression of MIR100HG and CBX6 was enhanced, while miR-146b-5p was inhibited in HCC cells. High MIR100HG expression was positively associated with the TNM tumor stage and Edmondson-Steiner grading in HCC patients. MIR100HG knockdown considerably reduced the HCC cell viability, migration, and invasion. In addition, MIR100HG directly targeted miR-146b-5p, and miR-146b-5p directly targeted CBX6 in HCC cells. Moreover, miR-146b-5p suppression or CBX6 elevation evidently rescued the suppressed viability, migration, and invasion of HCC cells caused by MIR100HG knockdown.

Conclusions. Knockdown of MIR100HG inhibited the viability, migration, and invasion of HCC cells by targeting the miR-146b-5p/CBX6 axis, offering a potential therapeutic target for HCC therapy.

1. Introduction

Primary liver cancer is the fourth most common reason of cancer mortality [1]. Hepatocellular carcinoma (HCC) is a frequently malignant tumor of primary liver cancer [2]. HCC is usually accompanied by cirrhosis and chronic viral hepatitis B or C [3]. Despite advances in the clinical treatment of HCC, the prognosis for HCC patients is still poor [4]. Thus, it is crucial to discover new therapeutic targets for HCC treatment.

Emerging evidences reveal that long noncoding RNAs (lncRNAs) are involved in the regulation of cell proliferation, migration, and invasion in several types of human cancers, such as osteosarcoma [5], breast cancer [6], and lung cancer [7]. Surely, some lncRNAs acting as oncogenes are also reported to participate in HCC tumorigenesis. IncRNA FAL1 inhibits miR-1236 expression to promote HCC cell proliferation and metastasis [8]. IncRNA KTN1-S1 silencing reduces viability and triggers apoptosis of HCC cells [9]. IncRNA MALAT1 contributes to HCC progression via mTOR activation and SRSF1 elevation [10]. It has been documented that IncRNA MIR100HG (MIR100HG) serves as an oncogene to take part in solid tumors. MIR100HG overexpression accelerates the metastasis of colorectal cancer and is related to poor outcome [11]. MIR100HG overexpression accelerates the laryngeal squamous cell carcinoma progression by inhibiting miR-204-5p [12]. Elimination of MIR100HG
attenuates the cell proliferation in gastric cancer [13]. However, the specific regulatory function of MIR100HG in HCC remains unknown.

Certain microRNAs (miRNAs) have been determined to participate in HCC. miR-200b overexpression inhibits HCC cell growth via suppressing HMGB3 expression [14]. miR-490-5p represses the ECT2 and E2F2 expression to attenuate metastasis of HCC [15]. miR-136 regulates the COX2 expression, thus restraining the malignant progression of HCC cells [16]. miR-146b-5p acts as an anti-oncomiR in diverse cancers. miR-146b-5p elevation inhibits NOTCH1 to decrease T-cell acute lymphoblastic leukemia progression [17]. miR-146b-5p deficiency enhances glioma cell growth while it attenuates apoptosis by regulating TRAF6 [18]. Notably, miR-146b-5p exerts the tumor inhibitory effect by retarding the phosphorylation of Akt in HCC [19]. However, the regulatory relationship between MIR100HG and miR-146b-5p in HCC remains unclear.

Chromobox 6 (CBX6), one of the polycomb paralogs, functions in cancer progression [20]. Certain CBX family members exert a tumor-promoting role in HCC. CBX8 interacts with YBX1 to accelerate HCC cell proliferation [21]. CBX4 silencing impairs cell cycle progression and hampers cell proliferation in HCC [22]. Importantly, CBX6 overexpression is an independent prognostic factor for shorter overall survival of HCC patients [23]. However, the regulatory relationship between MIR100HG and CBX6 in HCC remains unclear.

Herein, we evaluated the expression and functions of MIR100HG in HCC. Additionally, the relationships between MIR100HG, miR-146b-5p, and CBX6 in HCC were confirmed. This study may provide a novel therapeutic target for HCC.

2. Material and Method
2.1. Human Samples. Fifty HCC patients who underwent hepatectomy from June 2017 to March 2019 at our hospital were enrolled in this study. Fifty HCC tissue specimens (tumor group) and paired adjacent tissues (normal group) were obtained from the HCC patients who underwent hepatectomy. Prior to hepatectomy, no radiotherapy or chemotherapy treatment was administered to the patients. The patient cohort was separated into high MIR100HG (n = 25) and low MIR100HG groups (n = 25) according to the median MIR100HG expression. This study was permitted by our hospital ethics committee, and informed consent was obtained from each patient.

2.2. Cell Culture. The Hep3B, HepG2, SK-HEP1, and Huh7 HCC cell lines and normal LO2 liver cell line (American Type Culture Collection, Manassas VA, USA) were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, Carlsbad, CA, USA) supplied with 10% fetal bovine serum (FBS) at 37°C with 5% CO2.

2.3. Cell Transfection. The small interfering (si) MIR100HG-1, si-MIR100HG-2, si-negative control (NC), miR-146b-5p mimics, mimic NC, miR-146b-5p inhibitor, inhibitor NC, pcDNA3.1 (pcDNA)-CBX6, and pcDNA-NC were synthesized by GenePharma (Shanghai, China). Hep3B and SK-HEP1 cells grown to 80% confluence were transfected or cotransfected with these above agents using the Lipofectamine 3000 reagent (Invitrogen). Forty-eight hours posttransfection, Hep3B and SK-HEP1 cells were used for further assays.

2.4. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) and Western Blot. qRT-PCR and western blot were performed as previously described [24]. The primers are depicted in Table 1. MIR100HG, miR-146b-5p, and CBX6 expression was normalized to GAPDH, U6, and β-actin expression. The antibodies for western blot analysis including anti-CBX6 (1:1000, av39074, Sigma, St. Louis, MO, USA), anti-GAPDH (1:1000, G9545, Sigma), and HRP-conjugated secondary antibody (1:2000, 12-348, Sigma). The protein bands were visualized by enhanced chemiluminescence exposure solution and quantified by ImageLab software (Bio-Rad, Hercules, CA, USA).

2.5. MTT Assay. Hep3B and SK-HEP1 cells (2 × 10^4/well) were seeded into 96-well plates and incubated at 37°C with 5% CO2. At each time point (0, 24, 48, and 72 h posttransfection), cell proliferation was determined using MTT assay.

### Table 1: Primer sequences.

| Name of primer | Sequences (5′-3′) |
|----------------|------------------|
| MIR100HG-F     | CCCAGTGGAAAGGAAAAAGA |
| MIR100HG-R     | GCAAGGAGGTGTTCCTCAGG |
| GAPDH-F        | GGGAAATTCACCAGGACAGT |
| GAPDH-R        | AGATGCTGATGGGCTTCCC |
| miR-146b-5p-F  | ACACCTCGGCTGGTGAACGTGAAATCGAATTCCA |
| miR-146b-5p-R  | TGGGTGCTGTGAGTCGGCAATT |
| U6-F           | CTCGGTCTGGCCACGACCA |
| U6-R           | AACGCTTACGAAATTGCGT |
| CBX6-F         | AGATGTCAACCTGCTCAAT |
| CBX6-R         | AGCCACCTTCTCGAAAATCC |
| β-Actin-F      | AGAAATCTCGGACCCACACC |
| β-Actin-R      | AGAGCCGTACGAGGATAGCA |
viability was measured via the MTT cell viability assay kit (Sigma) by the manufacturer.

2.6. Wound Healing Assay. Hep3B and SK-HEP1 cells (1 × 10⁶/well) were incubated in 6-well plates. The cell monolayer was then wounded with a 10 μl pipette tip and cultured in serum-free medium. Cell migration images were captured at 0 and 24 h.

2.7. Invasion Assay. A Transwell chamber (8 mm, Corning Incorporated, Corning, NY, USA) was used to measure cell invasion. Briefly, Hep3B and SK-HEP1 cells (2.5 × 10⁵/well) in serum-free medium were added into the upper chamber. Medium containing 10% FBS was added to the lower chamber and acted as a chemoattractant. After 24 h, cells that had invaded the pore were fixed with methanol and stained with 0.05% crystal purple. The invading cells were counted.

2.8. Dual-Luciferase Reporter Assay. The potential binding sites of MIR100HG and miR-146b-5p or miR-146b-5p and CBX6 were predicted by starBase or TargetScan, respectively. We generated MIR100HG and CBX6 sequences with WT or MUT miR-146b-5p-binding sites and cloned them in the pmiRGO vector (YouBio, Hunan, China). Hep3B and SK-HEP1 cells were cotransfected with above luciferase vectors and mimic NC or miR-146b-5p mimics using Lipofectamine 3000 (Invitrogen).

2.9. Statistical Analyses. All statistical analyses were performed using GraphPad Prism (version 8.0). Data are

![Graph](image_url)

**Table 2.** Correlation between MIR100HG expression and clinicopathological features in hepatocellular carcinoma patients.

| Characteristics            | n (High) | n (Low) | P value |
|----------------------------|----------|---------|---------|
| Age                        |          |         |         |
| <50 years                  | 24       | 11      | 0.921   |
| ≥50 years                  | 26       | 14      | 12      |
| Gender                     |          |         |         |
| Male                       | 29       | 16      | 13      |
| Females                    | 21       | 9       | 12      |
| Liver cirrhosis            |          |         |         |
| Yes                        | 38       | 20      | 18      |
| No                         | 12       | 5       | 7       |
| Tumor size                 |          |         |         |
| <5 cm                      | 32       | 18      | 14      |
| ≥5 cm                      | 18       | 7       | 11      |
| TNM tumor stage            |          |         |         |
| I+II                       | 28       | 19      | 9       |
| III+IV                     | 22       | 6       | 16      |
| Edmondson-Steiner grading  |          |         |         |
| I+II                       | 31       | 21      | 10      |
| III+IV                     | 19       | 4       | 15      |

Note: *P < 0.05.
presented as the mean ± SD. The differences between two groups or among multiple groups were assessed by Student’s t-test or one-way ANOVA followed by Tukey’s post hoc test. The significance of the correlations was determined by Pearson’s correlation analysis. P values < 0.05 were considered statistically significant.

3. Results

3.1. MIR100HG Expression Enhanced in HCC. Figure 1(a) exhibits that MIR100HG expression was considerably increased in tumor tissues of HCC patients (P < 0.001). Besides, MIR100HG expression was clearly enhanced in tumors at
Figure 3: miR-146b-5p was directly targeted by MIR100HG. (a) starBase displayed the predicted binding site between MIR100HG and miR-146b-5p. (b) Relative luciferase activity in Hep3B and SK-HEP1 cells was measured by the dual-luciferase reporter assay. **P < 0.01 vs. mimic NC. (c) The expression of miR-146b-5p was upregulated by the transfection of si-MIR100HG-1 in Hep3B and SK-HEP1 cells. ***P < 0.001 vs. si-NC. (d) qRT-PCR was performed to determine the expression of miR-146b-5p in hepatocellular carcinoma (HCC) tumor tissues and adjacent tissues. *P < 0.05 vs. normal. (e) The expression of MIR100HG was negatively correlated with miR-146b-5p in HCC tumor tissues. (f) The expression of miR-146b-5p in LO2, Hep3B, HepG2, SK-HEP1, and Huh7 cells was detected by qRT-PCR. ***P < 0.001 vs. LO2.
Figure 4: Continued.
TNM III/IV ($P < 0.01$, Figure 1(b)). As depicted in Table 2, increased MIR100HG expression was related to the TNM tumor stage and Edmondson-Steiner grading in HCC patients ($P < 0.05$). Moreover, MIR100HG expression was dramatically upregulated in Hep3B, HepG2, SK-HEP1, and Huh7 cells compared to that in LO2 cells ($P < 0.001$, Figure 1(c)).

### 3.2. MIR100HG Knockdown Attenuated the Tumorigenesis of HCC Cells

MIR100HG was blocked by transfecting with si-MIR100HG-1 ($P < 0.001$) and si-MIR100HG-2 ($P < 0.01$) in Hep3B and SK-HEP1 cells (Figure 2(a)). si-MIR100HG-1 was used for subsequent assays because of high silence efficiency. The MTT assay demonstrated that si-MIR100HG-1 markedly reduced the viability of Hep3B and SK-HEP1 cells ($P < 0.001$, Figure 2(b)). As illustrated in Figures 2(c) and 2(d), the migration and invasion of Hep3B and SK-HEP1 cells were visibly inhibited following MIR100HG knockdown ($P < 0.01$).

### 3.3. miR-146b-5p Was Directly Targeted by MIR100HG

Bioinformatics analysis was performed with StarBase to predict that MIR100HG directly targets miR-146b-5p (Figure 3(a)). To demonstrate this prediction, the dual-luciferase reporter assay was used, and the results discovered that fluorescence intensity was clearly constrained in Hep3B and SK-HEP1 cells after being transfected with MIR100HG 3′UTR-WT and miR-146b-5p mimics ($P < 0.01$, Figure 3(b)). MIR100HG knockdown could markedly upregulate miR-146b-5p expression in Hep3B and SK-HEP1 cells ($P < 0.001$, Figure 3(c)). Additionally, miR-146b-5p expression was considerably suppressed in tumor tissues of HCC patients ($P < 0.01$, Figure 3(d)). Interestingly, MIR100HG and miR-146b-5p expression was negatively correlated in tumor tissues ($R^2 = 0.0879$, $P = 0.0356$, Figure 3(e)). miR-146b-5p expression was clearly inhibited in Hep3B, HepG2, SK-HEP1, and Huh7 cells compared with that in LO2 cells ($P < 0.001$, Figure 3(f)).

### 3.4. miR-146b-5p Restrained the Tumorigenesis of HCC Cells

miR-146b-5p was elevated or inhibited by transfecting with miR-146b-5p mimics or miR-146b-5p inhibitor in Hep3B and SK-HEP1 cells ($P < 0.001$, Figure 4(a)). miR-146b-5p elevation strikingly attenuated the viability of Hep3B and SK-HEP1 cells ($P < 0.001$, Figure 4(b)). Beside, miR-146b-5p significantly impeded the migration and invasion of Hep3B and SK-HEP1 cells ($P < 0.01$, Figures 4(c) and 4(d)).

### 3.5. miR-146b-5p Directly Targeted CBX6

The binding site of miR-146b-5p, as predicted by TargetScan, was at the 3′UTR of CBX6 (Figure 5(a)). The dual-luciferase reporter assay revealed that fluorescence intensity was visibly suppressed in Hep3B and SK-HEP1 cells after being transfected with CBX6 3′UTR-WT and miR-146b-5p mimics ($P < 0.001$, Figure 5(b)). Besides, miR-146b-5p elevation obviously repressed the CBX6 protein expression in Hep3B and SK-HEP1 cells ($P < 0.001$, Figure 5(c)). Moreover, CBX6 expression was dramatically elevated in tumor tissues of HCC patients ($P < 0.01$, Figure 5(d)). There were a negative correlation between CBX6 and miR-146b-5p expression ($R^2 = 0.0797$, $P = 0.0470$, Figure 5(e)) and a positive correlation between CBX6 and MIR100HG expression in HCC tissues ($R^2 = 0.0785$, $P = 0.0488$, Figure 5(f)). CBX6 expression was visibly increased in Hep3B, HepG2, SK-HEP1, and Huh7 cells compared to that in LO2 cells ($P < 0.01$, Figure 5(g)).

### 3.6. MIR100HG Deficiency Suppressed the Tumorigenesis of HCC Cells by Targeting the miR-146b-5p/CBX6 Axis

Figure 6(a) displays that CBX6 expression was clearly elevated by transfecting with pcDNA-CBX6 in Hep3B cells ($P < 0.001$). Decreased CBX6 protein expression by MIR100HG knockdown in Hep3B cells was rescued by miR-146b-5p suppression ($P < 0.001$, Figure 6(b)). We further explored the molecular mechanism by which MIR100HG knockdown inhibited the tumorigenesis of HCC cells, using rescue experiments. As exhibited in Figures 6(c) – 6(e), miR-146b-5p elimination or CBX6 overexpression evidently prevented the inhibitory effects of MIR100HG suppression on Hep3B cell viability, migration, and invasion ($P < 0.01$).
CBX6 WT: 5′ gaccagggucuguGUUCUCc 3′
miR-146b-5p: 3′ ucggauaccuaagucAAGAGu 5′
CBX6 MUT: 5′ gaccagggucuguCAAGAGc 3′

(a)

(b)

(c)

(d)

(e)

Figure 5: Continued.
**4. Discussion**

The lncRNA elevation often facilitates HCC progression [25]. The expression of lncRNAs, such as MALAT1 [10], AB019562 [24], and CARLo-5 [26], is enhanced in HCC patients. In the present research, MIR100HG expression was elevated in HCC, indicating that MIR100HG may be an oncogenic lncRNA in HCC. Besides, MIR100HG expression was found to be correlated with the TNM tumor stage and Edmondson-Steiner grading in HCC patients. Some lncRNAs have the same function in HCC. IncRNA CARLo-5 is upregulated in HCC patients with a higher Edmondson-Steiner grade [26]. High-level IncRNA LINC00470 is markedly correlated with an advanced TNM stage in HCC patients [27]. Above all, MIR100HG expression was enhanced in HCC and related to the HCC progression. Numerous researches have demonstrated that MIR100HG partakes in tumor behavior of different cancers [11, 12]. Knockdown of MIR100HG has an inhibitory effect on the tumorigenesis of cancers. For instances, MIR100HG suppression impairs the cell viability, thus attenuating the tumorigenesis of acute megakaryoblastic leukemia [28]. MIR100HG deficiency impedes cell viability while accelerating cell apoptosis to suppress HCC progression [29]. MIR100HG silencing upregulates miR-5590-3p and downregulates OTX1, resulting in the decrease in cell viability and invasion in breast cancer [30]. In this study, MIR100HG knockdown decreases the HCC cell viability, invasion, and migration, suggesting that MIR100HG acts as a therapeutic target for HCC treatment. In addition, sorafenib, an oral kinase inhibitor, has been confirmed to be a gold quality standard to enhance survival in patients affected by advanced HCC in the first-line treatment [31]. Interestingly, numerous lncRNAs are overexpressed in HCC tissues and are closely associated with sorafenib resistance, such as SNHG1 [32], SNHG3 [33], HEIH [34], and NEAT1 [35]. We speculated that the high expression level of MIR100HG may also promote sorafenib resistance to affect the progression of HCC when sorafenib is administered in clinical practice. Further researches on the interaction of MIR100HG with sorafenib are urgently needed.

lncRNAs often function as a molecular sponge or competing endogenous RNA in regulating miRNA in HCC. For instances, IncRNA n335586 facilitates CKMT1A expression through competitively binding with miR-924 to enhance HCC cell migration and invasion [36]. IncRNA SNHG15 serves as a molecular sponge of miR-141-3p to exert its onco-gene function [37]. Notably, IncRNA MALAT1 accelerates HCC progression via sponging miR-146b-5p [19]. Here, miR-146b-5p was a target of MIR100HG and negatively related to MIR100HG expression, indicating that MIR100HG may be involved in HCC by regulating miR-146b-5p. miR-146b-5p is often inhibited in solid tumors, such as glioma [38] and gallbladder cancer [39]. In this study, miR-146b-5p was suppressed in HCC, suggesting that miR-146b-5p may act as an anti-oncomiR in HCC. It has been documented that miR-146b-5p serves as a mediator in tumor progression. miR-146b-5p upregulation leads to MMP16 knockdown, thus hindering glioma cell growth [38], miR-146b-5p overexpression retards cell proliferation and facilitates cell apoptosis in nasopharyngeal carcinoma by regulating HNRNPA2B1 [40]. Importantly, miR-146b-5p is inhibited in HCC cells and is a biomarker for the gene therapy of HCC [41]. Here, we determined that miR-146b-5p restrained tumorigenesis of HCC cells, and miR-146b-5p deficiency weakened the antitumor function of MIR100HG suppression in HCC cells. Taken together, MIR100HG silencing may inhibit tumorigenesis of HCC cells through upregulating miR-146b-5p.

CBX family members are frequently elevated in various tumors, such as CBX2 in ovarian cancer [42], CBX4 in breast cancer [43], and CBX8 in muscle invasive bladder cancer [44].
Figure 6: Continued.
Similarly, CBX6 expression was increased in HCC in this study, indicating that CBX6 may be a participant in HCC. CBX family numbers are involved in HCC progression. CBX1 interacts with HMGA2 to accelerate HCC cell proliferation and migration [45]. CBX2 suppression attenuates proliferation and induces apoptosis in HCC cells by modulating YAP [46]. Notably, CBX6 elevation promotes HCC cell growth and is predictive of a poor outcome in HCC [47]. Additionally, the CBX family member can be involved in HCC progression as a target gene for miRNAs. For example, miR-195 overexpression restrains proliferative and invasive capacities of the HCC cells by inhibiting CBX4 [48]. In the present study, CBX6 was demonstrated to be a target of miR-146b-5p, which was inversely modulated through miR-146b-5p. We assumed that miR-146b-5p may suppress HCC progression through inhibiting CBX6. Furthermore, we discovered that CBX6 expression was positively related to MIR100HG in HCC. Considering the MIR100HG/miR-146b-5p axis, we speculated that MIR100HG may influence CBX6 via modulating miR-146b-5p. Importantly, rescue experiment exhibited that CBX6 overexpression reversed the suppressed HCC cell behaviors caused by MIR100HG silencing. To sum up, MIR100HG silencing may attenuate the tumorigenesis of HCC cells by regulating the miR-146b-5p/CBX6 axis. Additionally, the expression of MIR100HG/miR-146b-5p/CBX6 in HCC tissues was based on hepatectomy in this study. In many cases, however, biomarkers are not uniformly present in all cancer cells, and such heterogeneity might hinder the therapeutic efficacy of tailored therapies [49]. In recent years, there has been an increasing development of liquid biopsy to replace tissue biopsy [50]. Blood-based liquid biopsy consists in the isolation and analysis of tumor-derived or tumor-associated components that circulate in the bloodstream, including circulating tumor cells (CTCs), circulating leukocytes, and tumor-derived circulating nucleic acids, such as cell-free circulating tumor DNA (ctDNA), miRNA, and lncRNAs [51, 52]. In fact, these components are deeply involved in the epithelial-to-mesenchymal transition (EMT) process of HCC, which greatly affects cell invasion and migration [53–55]. We speculated that if so, the measurement of MIR100HG/miR-146b-5p/CBX6 expression by liquid biopsy may be a more efficient and rapid method to determine

**Figure 6:** MIR100HG deficiency suppressed the tumorigenesis of hepatocellular carcinoma (HCC) cells by targeting the miR-146b-5p/CBX6 axis. (a) The transfection efficiency of pcDNA-NC and pcDNA-CBX6 was measured by qRT-PCR in Hep3B cells. ***P < 0.001 vs. pcDNA-NC. (b) Western blot was performed to measure the protein expression of CBX6 in Hep3B cells. ***P < 0.001 vs. pcDNA-NC, **P < 0.01 vs. si-MIR100HG-1. (c–e) Inhibition of miR-146b-5p or overexpression of CBX6 reversed the inhibitory effects of MIR100HG knockdown on viability, migration, and invasion of Hep3B cells. **P < 0.01, ***P < 0.001 vs. si-NC; ### P < 0.001 vs. si-MIR100HG-1.
whether the metastasis occurs in HCC patients. This may be also a limitation of this study, and we will consider this in future studies. Even so, our findings for the first time uncover new insight for the molecular mechanism of HCC and provide a potential target for HCC treatment.

Data Availability

All data are available through the responsible corresponding author.

Ethical Approval

This study was conducted after obtaining local ethical committee approval of Wei Fang Yi Du Central Hospital (no. 2017-002). We confirm that all experiments were performed following relevant named institutional and national guidelines and regulations.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Authors’ Contributions

Fushun Li and Xianghua Sun were responsible for the conceptualization. Fushun Li and Xianghua Sun were responsible for the formal analysis. Fushun Li, Xianghua Sun, and Qing Liu were responsible for the investigation. Xilu Liu and Jia Zhang were responsible for the methodology. Fushun Li, Xianghua Sun, and Qing Liu wrote the original draft. Fushun Li, Xianghua Sun, Xilu Liu, and Jia Zhang reviewed and edited the manuscript. All authors approved the final manuscript. Fushun Li and Xianghua Sun are co-first authors.

References

[1] A. Villanueva, “Hepatocellular carcinoma,” The New England Journal of Medicine, vol. 380, no. 15, pp. 1450–1462, 2019.

[2] A. J. Craig, J. von Felden, T. Garcia-Lezana, S. Sarcognato, and A. Villanueva, “Tumour evolution in hepatocellular carcinoma,” Nature Reviews. Gastroenterology & Hepatology, vol. 17, no. 3, pp. 139–152, 2020.

[3] M. F. CHEDID, C. R. P. KRUEL, M. A. PINTO et al., “Hepatocellular carcinoma: diagnosis and operative management,” Arquivos Brasileiros de Cirurgia Digestiva, vol. 30, no. 4, pp. 272–278, 2017.

[4] J. Hartke, M. Johnson, and M. Ghabrial, “The diagnosis and treatment of hepatocellular carcinoma,” Seminars in Diagnostic Pathology, vol. 34, no. 2, pp. 153–159, 2017.

[5] S. Liu and X. Meng, “LINC00662 long non-coding RNA knockdown attenuates the proliferation, migration, and invasion of osteosarcoma cells by regulating the microRNA-15a-5p/Notch2 axis,” Oncotargets and Therapy, vol. Volume 13, pp. 7517–7530, 2020.

[6] W. Zhao, D. Geng, S. Li, Z. Chen, and M. Sun, “LncRNA HOTAIR influences cell growth, migration, invasion, and apoptosis via the miR-20a-5p/HMGA2 axis in breast cancer,” Cancer Medicine, vol. 7, no. 3, pp. 842–855, 2018.

[7] L. Chen, C. H. Qiu, Y. Chen, Y. Wang, J. J. Zhao, and M. Zhang, “LncRNA SNHG16 drives proliferation, migration, and invasion of lung cancer cell through modulation of miR-520/VEGF axis,” European Review for Medical and Pharmacological Sciences, vol. 24, no. 18, pp. 9522–9531, 2020.

[8] B. Li, R. Mao, C. Liu, W. Zhang, Y. Tang, and Z. Guo, “LncRNA FAL1 promotes cell proliferation and migration by acting as a CeRNA of miR-1236 in hepatocellular carcinoma cells,” Life Sciences, vol. 197, pp. 122–129, 2018.

[9] L. Zhang, L. Wang, Y. Wang et al., “LncRNA KTN1-AS1 promotes tumor growth of hepatocellular carcinoma by targeting miR-23c/ERBB2IP axis,” Biomedicine & Pharmacotherapy, vol. 109, pp. 1140–1147, 2019.

[10] P. Malakar, A. Shilo, A. Mogilevsky et al., “Long noncoding RNA MALAT1 promotes hepatocellular carcinoma development by SRSF1 upregulation and mTOR activation,” Cancer Research, vol. 77, no. 5, pp. 1155–1167, 2017.

[11] W. Li, F. Yuan, X. Zhang, W. Chen, X. Tang, and L. Lu, “Elevated MIR100HG promotes colorectal cancer metastasis and is associated with poor prognosis,” Oncology Letters, vol. 18, no. 6, pp. 6483–6490, 2019.

[12] Y. Huang, C. Zhang, and Y. Zhou, “LncRNA MIR100HG promotes cancer cell proliferation, migration and invasion in laryngeal squamous cell carcinoma through the downregulation of miR-204-5p,” Oncotargets and Therapy, vol. Volume 12, pp. 2967–2973, 2019.

[13] J. Li, Q. Xu, W. Wang, and S. Sun, “MIR100HG: a credible prognostic biomarker and an oncogenic lncRNA in gastric cancer,” Biosciences Reports, vol. 39, no. 4, 2019.

[14] L. K. Wang, X. N. Xie, H. H. Song et al., “Upregulation of miR-200b inhibits hepatocellular carcinoma cell proliferation and migration by targeting HMGB3 protein,” Technology in Cancer Research & Treatment, vol. 17, p. 15330381806047, 2018.

[15] Z. Q. Fang, M. C. Li, Y. Q. Zhang, and X. G. Liu, “miR-490-5p inhibits the metastasis of hepatocellular carcinoma by down-regulating E2F2 and ECT2,” Journal of Cellular Biochemistry, vol. 119, no. 10, pp. 8317–8324, 2018.

[16] H. Jia, H. Wang, Y. Yao, C. Wang, and P. Li, “miR-136 inhibits malignant progression of hepatocellular carcinoma cells by targeting cyclooxygenase 2,” Oncology Research, vol. 26, no. 6, pp. 967–976, 2018.

[17] Y. Y. Luo, Z. H. Wang, Q. Yu, L. L. Yuan, H. L. Peng, and Y. X. Xu, “LncRNA-NEAT1 promotes proliferation of T-ALL cells via miR-146b-5p/NOTCH1 signaling pathway,” Pathology, Research and Practice, vol. 216, no. 11, p. 153212, 2020.

[18] Z. Qian, S. Zhou, Z. Zhou et al., “miR-146b-5p suppresses glioblastoma cell resistance to temozolomide through targeting TRAF6,” Oncology Reports, vol. 38, no. 5, pp. 2941–2950, 2017.

[19] C. Li, R. Miao, S. Liu et al., “Down-regulation of miR-146b-5p by long noncoding RNA MALAT1 in hepatocellular carcinoma promotes cancer growth and metastasis,” Oncotarget, vol. 8, no. 17, pp. 28683–28695, 2017.

[20] N. Milosevich, M. C. Gignac, J. McFarlane et al., “Selective inhibition of CBX6: a methyllysine reader protein in the polycomb family,” ACS Medicinal Chemistry Letters, vol. 7, no. 2, pp. 139–144, 2016.

[21] L. Xiao, Z. Zhou, W. Li et al., “Chromobox homolog 8 (CBX8) interacts with Y-box binding protein 1 (YBX1) to promote cellular proliferation in hepatocellular carcinoma cells,” Aging, vol. 11, no. 17, pp. 7123–7149, 2019.
[22] B. Wang, J. Tang, D. Liao et al., “Chromobox homolog 4 is correlated with prognosis and tumor cell growth in hepatocellular carcinoma,” Annals of Surgical Oncology, vol. 20, no. 3, pp. 13–3171, 2021.

[23] G. Ning, Y. L. Huang, L. M. Zhen et al., “Transcriptional expressions of chromobox 1/2/3/6/8 as independent indicators for survivals in hepatocellular carcinoma patients,” Aging, vol. 10, no. 11, pp. 3450–3473, 2018.

[24] F. Wu, J. Li, X. Du, W. Zhang, P. Lei, and Q. Zhang, “Long non-coding RNA AB019562 promotes cell proliferation and metastasis in human hepatocellular carcinoma,” Molecular Medicine Reports, vol. 16, no. 1, pp. 69–74, 2017.

[25] C. L. Kang, B. Qi, Q. Q. Cai et al., “miR-145 promotes hepatocellular carcinoma metastasis by stimulating ITGA5 trans-cription,” Theranostics, vol. 9, no. 15, pp. 4421–4436, 2019.

[26] F. Wang, C. Xie, W. Zhao, Z. Deng, H. Yang, and Q. Fang, “Long non-coding RNA CARLo-5 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients,” Clinical and Experimental Medicine, vol. 17, no. 1, pp. 33–43, 2017.

[27] W. Huang, J. Liu, J. Yan et al., “LncRNA LINC00470 promotes proliferation through association with NF45/NF90 complex in hepatocellular carcinoma,” Human Cell, vol. 33, no. 1, pp. 131–139, 2020.

[28] S. Emmrich, A. Streltsov, F. Schmidt, V. R. Thangapandi, D. Reinhardt, and J. H. Klußmann, “LncRNAs MONC and MIR100HG act as oncogenes in acute megakaryoblastic leukemia,” Molecular Cancer, vol. 13, no. 1, pp. 171–4598, 2014.

[29] X. Su, J. Teng, G. Jin et al., “ELK1-induced upregulation of long non-coding RNA MIR100HG predict poor prognosis and promotes the progression of osteosarcoma by epigenetically silencing LATS1 and LATS2,” Biomedicine & Pharmacotherapy, vol. 109, pp. 788–797, 2019.

[30] F. Y. Chen, Z. Y. Zhou, K. J. Zhang, J. Pang, and S. M. Wang, “Long non-coding RNA MIR100HG promotes the migration, invasion and proliferation of triple-negative breast cancer cells by targeting the miR-5590-3p/OTX1 axis,” Cancer Cell International, vol. 20, no. 508, pp. 20–1580, 2020.

[31] O. Brunetti, A. Gnoni, A. Licchetta et al., “Predictive and prognostic factors in HCC patients treated with sorafenib,” Medicina, vol. 55, no. 10, pp. 707, 2019.

[32] W. Li, X. Dong, C. He et al., “LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells,” Journal of Experimental & Clinical Cancer Research, vol. 38, no. 1, p. 183, 2019.

[33] P. F. Zhang, F. Wang, J. Wu et al., “LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR-128/CD151 pathway in hepatocellular carcinoma,” Journal of Cellular Physiology, vol. 234, no. 3, pp. 2788–2794, 2019.

[34] Q. Shen, S. Jiang, M. Wu, L. Zhang, X. Su, and D. Zhao, “LncRNA HEIH confers cell sorafenib resistance in hepatocellular carcinoma by regulating miR-98-5p/P13K/AKT pathway,” Cancer Management and Research, vol. 12, pp. 6585–6595, 2020.

[35] Y. Niu, G. Tang, X. Wu, and C. Wu, “LncRNA NEAT1 modulates sorafenib resistance in hepatocellular carcinoma through regulating the miR-149-5p/AKT1 axis,” Saudi Journal of Gastroenterology, vol. 26, no. 4, p. 194, 2020.

[36] H. Fan, P. Lv, T. Mu et al., “LncRNA n335586/miR-924/CKMT1A axis contributes to cell migration and invasion in hepatocellular carcinoma cells,” Cancer Letters, vol. 429, pp. 89–99, 2018.

[37] J. Ye, L. Tan, Y. Fu et al., “LncRNA SNHG15 promotes hepatocellular carcinoma progression by spongeing miR-141-3p,” Journal of Cellular Biochemistry, vol. 120, no. 12, pp. 19775–19783, 2019.

[38] Y. Li, Y. Wang, L. Yu et al., “miR-146b-5p inhibits glioma migration and invasion by targeting MMP16,” Cancer Letters, vol. 339, no. 2, pp. 260–269, 2013.

[39] Y. P. Lv, W. Shi, H. X. Liu, X. J. Kong, and D. L. Dai, “Identification of miR-146b-5p in tissues as a novel biomarker for prognosis of gallbladder carcinoma,” European Review for Medical and Pharmacological Sciences, vol. 21, no. 3, pp. 518–522, 2017.

[40] E. Zhang and X. Li, “LncRNA SOX2-OT regulates proliferation and metastasis of nasopharyngeal carcinoma cells through miR-146b-5p/HNRNPAB1 pathway,” Journal of Cellular Biochemistry, vol. 120, no. 10, pp. 16575–16588, 2019.

[41] W. Ding, H. Yang, S. Gong et al., “Candidate miRNAs and pathogenesis investigation for hepatocellular carcinoma based on bioinformatics analysis,” Oncology Letters, vol. 13, no. 5, pp. 3409–3414, 2017.

[42] L. J. Wheeler, Z. L. Watson, L. Qamar et al., “CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer,” Oncogene, vol. 7, no. 11, pp. 92–103, 2018.

[43] J. S. Zeng, Z. D. Zhang, L. Pei et al., “CBX4 exhibits oncogenic activities in breast cancer via Notch1 signaling,” The International Journal of Biochemistry & Cell Biology, vol. 95, pp. 1–8, 2018.

[44] G. J. Yuan, X. Chen, J. Lu et al., “Chromobox homolog 8 is a predictor of muscle invasive bladder cancer and promotes cell proliferation by repressing the p53 pathway,” Cancer Science, vol. 108, no. 11, pp. 2166–2175, 2017.

[45] Y. F. Yang, Y. H. Pan, Q. H. Tian, D. C. Wu, and S. G. Su, “CBX1 indicates poor outcomes and exerts oncogenic activity in hepatocellular carcinoma,” Translational Oncology, vol. 11, no. 5, pp. 1110–1118, 2018.

[46] J. Mao, Y. Tian, C. Wang et al., “CBX2 regulates proliferation and apoptosis via the phosphorylation of YAP in hepatocellular carcinoma,” Journal of Cancer, vol. 10, no. 12, pp. 2706–2719, 2019.

[47] H. Zheng, W. H. Jiang, T. Tian et al., “CBX6 overexpression contributes to tumor progression and is predictive of a poor prognosis in hepatocellular carcinoma,” Oncotarget, vol. 8, no. 12, pp. 18872–18884, 2017.

[48] C. ZHENG, J. LI, Q. WANG et al., “MicroRNA-195 functions as a tumor suppressor by inhibiting CBX4 in hepatocellular carcinoma,” Oncology Reports, vol. 33, no. 3, pp. 1115–1122, 2015.

[49] I. Dagogo-Jack and A. T. Shaw, “Tumour heterogeneity and resistance to cancer therapies,” Nature Reviews. Clinical Oncology, vol. 15, no. 2, pp. 81–94, 2018.

[50] M. Russano, A. Napolitano, G. Ribelli et al., “Correction to: Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples,” Journal of Experimental & Clinical Cancer Research, vol. 39, no. 1, p. 120, 2020.

[51] K. Pantel and C. Alix-Panabieres, “Real-time liquid biopsy in cancer patients: fact or fiction?,” Cancer Research, vol. 73, no. 21, pp. 6384–6388, 2013.
[52] W. Zhang, W. Xia, Z. Lv, C. Ni, Y. Xin, and L. Yang, “Liquid biopsy for cancer: circulating tumor cells, circulating free DNA or exosomes?” Cellular Physiology and Biochemistry, vol. 41, no. 2, pp. 755–768, 2017.

[53] Y. F. Sun, W. Guo, Y. Xu et al., “Circulating tumor cells from different vascular sites exhibit spatial heterogeneity in epithelial and mesenchymal composition and distinct clinical significance in hepatocellular carcinoma,” Clinical Cancer Research, vol. 24, no. 3, pp. 547–559, 2018.

[54] S. Wang, J. Jiang, C. Zhang, X. Zhang, and C. Wang, “Serum lincRNA-p21 expression in primary liver diseases and liver metastatic diseases,” Pathology, Research and Practice, vol. 215, no. 4, pp. 779–783, 2019.

[55] Y. Gong, J. Mao, D. Wu et al., “Circ-ZEB1.33 promotes the proliferation of human HCC by sponging miR-200a-3p and upregulating CDK6,” Cancer Cell International, vol. 18, no. 1, 2018.